Farmacogenómica del metotrexate: estrategia para una terapéutica más individualizada en pacientes con artritis reumatoide

Mena-Ramírez, Juan Pablo; Salazar-Páramo, Mario; Dávalos-Rodríguez, Ingrid P.
Gac. méd. Méx ; 144(5): 449-451, sept.-oct. 2008. ilus
Artículo en Español | LILACS | ID: lil-568024

Documentos relacionados

  1. Development of Methotrexate Complexes Endowed with New Biological Properties Envisioned for Musculoskeletal Regeneration in Rheumatoid Arthritis Environments.
  2. [Pharmacogenomics of methrotexate: a strategy for a customized therapeutic scheme for patients with rheumatoid arthritis].
  3. Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review.
  4. Rhein methotrexate-decorated solid lipid nanoparticles altering adjuvant arthritis progression through endoplasmic reticulum stress-mediated apoptosis.
  5. A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis.
  6. Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
  7. Treating rheumatoid arthritis.
  8. 2023 International Consensus Guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis.
  9. Therapeutic Effect of Colony Stimulating Factor 1 Receptor Kinase Inhibitor, JTE-952, on Methotrexate-Refractory Pathology in a Rat Model of Rheumatoid Arthritis.
  10. Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial.